The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Valneva (VALN) stock is in focus as the U.S. recommends a pause in the company's chikungunya vaccine Ixchiq in adults 60+ ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports of serious adverse events (AEs) The US Food and Drug ...

U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

The U.S. health officials have recommended a pause in the use of French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq for those aged 60 years and older amid an ongoing safety review ...